產(chǎn)品中心Cell Resources
聯(lián)系我們CONTACT US
400-999-210024小時服務熱線
![K7M2 wt [K7M2-WT] (小鼠骨肉瘤成骨細胞) (STR鑒定正確)](/Public/upfile/pic/xbx/CL-0371-1.jpg)
![K7M2 wt [K7M2-WT] (小鼠骨肉瘤成骨細胞) (STR鑒定正確)](/Public/upfile/pic/xbx/CL-0371-2.jpg)
![K7M2 wt [K7M2-WT] (小鼠骨肉瘤成骨細胞) (STR鑒定正確)](/Public/upfile/pic/xbx/CL-0371-3.jpg)
![K7M2 wt [K7M2-WT] (小鼠骨肉瘤成骨細胞) (STR鑒定正確)](/Public/upfile/pic/xbx/CL-0371-4.jpg)
![K7M2 wt [K7M2-WT] (小鼠骨肉瘤成骨細胞) (STR鑒定正確)](/Public/upfile/pic/xbx/CL-0371-5.jpg)
![K7M2 wt [K7M2-WT] (小鼠骨肉瘤成骨細胞) (STR鑒定正確)](/Public/upfile/pic/xbx/CL-0371-6.jpg)
![K7M2 wt [K7M2-WT] (小鼠骨肉瘤成骨細胞) (STR鑒定正確)](/Public/upfile/pic/product/cell-line-new.jpg)
產(chǎn)品概述
| 名稱 | K7M2 wt [K7M2-WT] (小鼠骨肉瘤成骨細胞) (STR鑒定正確) |
| 別稱 | K7M2 wt; K7M2 |
| 種屬 | 小鼠 |
| 生長特性 | 貼壁細胞 |
| 細胞形態(tài) | 成骨細胞樣 |
| 凍存條件 | 凍存液：55% 基礎培養(yǎng)基+40%FBS+5%DMSO 溫度：液氮 |
| 培養(yǎng)方案A（默認） |
培養(yǎng)條件:
氣相：空氣，95%；CO2，5%, 溫度：37℃
|
| 推薦傳代比例 | 1:3-1:4 |
| 推薦換液頻率 | 2-3次/周 |
| 背景描述 | K7M2 wt [K7M2-WT]細胞抗原表達：Ⅷ因子、整合唾液酸蛋白(BSP)、二聚糖、飾膠蛋白聚糖、絨毛蛋白。此外，骨唾液酸蛋白、二聚糖、飾膠蛋白聚糖和骨調(diào)素的表達顯示K7M2 wt [K7M2-WT]細胞骨家族細胞特性。 |
| 年齡（性別） | 雌性；成年 |
| 組織來源 | 品系：BALB/c；器官：骨；疾?。汗侨饬觯粊碓崔D(zhuǎn)移灶：肺；細胞類型：成骨細胞 |
| 細胞類型 | 腫瘤細胞 |
| 腫瘤類型 | 肉瘤細胞 |
| 生物安全等級 | BSL-1 |
| 倍增時間 | ~31 hours |
| 致瘤性 | Yes, forms tumors in BALB/c mice with spontaneous metastasis to the lungs in over 90% of mice inoculated. |
| 抗原表達情況 | CD31+ |
| 基因表達情況 | secreted phosphoprotein 1 (osteopontin); factor VIII |
| 保藏機構 | ATCC; CRL-2836 |
STR鑒定
-
STR位點信息
18-3 18 6-7 12 5-5 14 X-1 25 1-2 17 7-1 29 8-1 13,14 1-1 16 19-2 13 15-3 22.3 12-1 17 6-4 18 4-2 21.3 3-2 12,13 2-1 16 13-1 16.2
11-2 18 17-2 16,17 -
STR鑒定圖
-
參考文獻
-
A bone-targeting permeable nanomicelle acting as an icebreaker for enhancing chemotherapy of osteosarcoma(2024/03/29)
作者：Bowen Duan, Hongting Liu, Xiaoxuan Ji
期刊：CHEMICAL ENGINEERING JOURNAL
影響因子 ：15.100
引用產(chǎn)品：CL-0371
-
Nanoengineering a metal–organic framework for osteosarcoma chemo-immunotherapy by modulating indoleamine-2,3-dioxygenase and myeloid-derived suppressor cells(2022/05/03)
作者：Qingxin Fan, Jing Zuo, Hailong Tian
期刊：JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
DOI：10.1186/s13046-022-02372-8
影響因子 ：11.300
引用產(chǎn)品：CL-0371
-
Tumor-oriented and chemo-photothermal nanoplatform capable of sensitizing chemotherapy and ferroptosis against osteosarcoma metastasis(2024/05/08)
作者：Hongzi Wu, Bowen Li, Jichun Shao
期刊：INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
DOI：10.1016/j.ijbiomac.2024.132019
影響因子 ：8.200
引用產(chǎn)品：CL-0371
-
Injectable thermosensitive black phosphorus nanosheet- and doxorubicin-loaded hydrogel for synergistic bone tumor photothermal-chemotherapy and osteogenesis enhancement(2023/03/25)
作者：Shihuai Li, Yunan Qing, Yan Lou
期刊：INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
DOI：10.1016/j.ijbiomac.2023.124209
影響因子 ：8.200
-
Investigating the synergy of Shikonin and Valproic acid in inducing apoptosis of osteosarcoma cells via ROS-mediated EGR1 expression(2024/02/15)
作者：Zhuo Chen, Fengfeng Wu, Jing Li
期刊：PHYTOMEDICINE
DOI：10.1016/j.phymed.2024.155459
影響因子 ：7.900
引用產(chǎn)品：CL-0371
-
MerTK-mediated efferocytosis promotes immune tolerance and tumor progression in osteosarcoma through enhancing M2 polarization and PD-L1 expression(2022/01/12)
作者：Jinti Lin, Ankai Xu, Jiakang Jin
期刊：OncoImmunology
DOI：10.1080/2162402X.2021.2024941
影響因子 ：7.200
-
Pharmacodynamics and pharmacokinetics of PLGA-based doxorubicin-loaded implants for tumor therapy(2022/02/29)
作者：Peng He, Shenglin Xu, Zehao Guo
期刊：Drug Delivery
DOI：10.1080/10717544.2022.2032878
影響因子 ：6.000
引用產(chǎn)品：CL-0371
-
Sulfatinib, a novel multi-targeted tyrosine kinase inhibitor of FGFR1, CSF1R, and VEGFR1–3, suppresses osteosarcoma proliferation and invasion via dual role in tumor cells and tumor microenvironment(2023/06/08)
作者：Song Liao, Jianxiong Li, Song Gao
期刊：Frontiers in Oncology
影響因子 ：4.700
-
LPS combined with CD47mAb enhances the anti?osteosarcoma ability of macrophages(2023/03/28)
作者：Peng Yuan, Yukang Que, Yulei Liu
期刊：Oncology Letters
影響因子 ：2.900
FAQs
Q：{{item.question}}
A：
產(chǎn)品資料
識別碼示意圖
